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Abstract  
We performed a clinicopathological study to assess the burden of small vessel disease (SVD) 
type of pathological changes in elderly demented subjects, who had clinical evidence of 
autonomic dysfunction, either carotid sinus hypersensitivity or orthostatic hypotension or 
both or had exhibited unexpected repeated falls.  Clinical and neuropathological diagnoses in 
112 demented subjects comprised dementia with Lewy bodies (DLB), Parkinson’s disease 
with dementia (PDD), Alzheimer’s disease (AD), Mixed dementia (mostly AD-DLB) and 
vascular dementia (VaD).  Of these, 12 DLB subjects had no recorded unexpected falls in life 
and therefore no evidence of concomitant autonomic dysfunction.  A further 17 subjects were 
assessed as ageing controls without significant pathology or signs of autonomic dysfunction.  
We quantified brain vascular pathological changes and determined severities of 
neurodegenerative lesions including g-synuclein pathology.  We found moderate-severe 
vascular changes and high vascular pathology scores (P<0.01) in all neurodegenerative 
dementias and as expected in VaD compared to similar age controls.  Arteriolosclerosis, 
perivascular spacing and microinfarcts were frequent in the basal ganglia and frontal white 
matter (WM) across all dementias whereas small infarcts (<5 mm) were restricted to VaD.  In 
a sub-set of demented subjects, we found that vascular pathology scores were correlated with 
WM hyperintensity volumes determined by MRI in life (P<0.02).  Sclerotic index values 
were increased by ~50% in both the WM and neocortex in all dementias compared to similar 
age controls.  We found no evidence for increased g-synuclein deposition in subjects with 
autonomic dysfunction.  Our findings suggest greater SVD pathological changes occur in the 
elderly diagnosed with neurodegenerative dementias including DLB and who acquire 
autonomic dysfunction.  SVD changes may not necessarily manifest in clinically overt 
symptoms but they likely confound motor or cognitive dysfunction.  We propose autonomic 
dysfunction promotes chronic cerebral hypoperfusion to impact upon ageing-related 
neurodegenerative processes and characterise their end-stage clinical syndromes.   
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Introduction 
Autonomic dysfunction occurs commonly after 50 years of age.  At least 40% of the elderly 
with Dementia with Lewy bodies (DLB), Parkinson’s disease with dementia (PDD), vascular 
dementia (VaD) and Alzheimer disease (AD) will exhibit some form of autonomic 
dysfunction.  They will invariably develop carotid sinus hypersensitivity (CSH), orthostatic 
hypotension (OH) or neurocardiovascular instability, associated with hypotension and 
bradycardia (2, 7, 23).   CSH involving an excessive fall in arterial pressure (53) is reported 
to occur in 35-58% of elderly with AD and DLB (24).  OH develops in nearly 50% of 
Parkinsonians (16, 18, 43, 49, 50) and may be present in over 90% of PDD patients (2).  OH
is an independent risk for incident dementia (9, 55) and often accompanied by disabling 
symptoms, impaired quality of life, dizziness, nausea, sweating, and loss of consciousness (1, 
4, 32).   
The vascular hypothesis of autonomic dysfunction proposes that recurrent episodic 
hypotension results in chronic cerebral hypoperfusion, especially in the frontal lobe.  This in 
turn causes anoxic damage and leads to impaired cognitive function (45).  While the true 
burden of asymptomatic autonomic dysfunction is unknown (31), it is crucial to protect the 
ageing brain from fluctuations between hyper- and hypotension, which are known to be 
associated with white matter (WM) changes (58).  We previously showed increased WM 
hyperintensities (WMHs) (24) in DLB patients with autonomic dysfunction.  WMHs are also 
associated with a postural drop in blood pressure in PD (39).  Here, we tested the hypothesis 
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that there is increased small vessel disease (SVD) or microvascular pathology in patients with 
clinical evidence of autonomic dysfunction or in those with repeated unexplained falls or 
syncope and progress to dementia.  We performed clinicopathological studies to explore the 
extent of SVD pathological changes (51) in patients exhibiting signs of autonomic 
dysfunction and had developed dementia.   
 
Materials and Methods 
Study design and subjects 
This study involved the assessment of a total of 129 subjects.  Demographic, clinical and 
pathological details of all the subjects are given in Tables 1 and 2.  Initially, we screened 
clinical records and post-mortem reports filed between 1992 and 2017.   Of the 350 records 
screened, we identified 77 demented subjects, who were assessed for autonomic function in 
the Falls and Syncope Service (FASS) at the Royal Victoria Infirmary, Newcastle upon Tyne 
and had had a post-mortem (Table 1).   We then found 23 additional dementia cases with 
clinical records reporting repeated unexplained falls prior to death.  This information was 
used as a proxy for the presence of autonomic dysfunction (1, 2).   In total, we identified 100 
demented subjects with direct clinical or reported evidence for autonomic dysfunction (Table 
2).  The unexplained falls in these individuals were deemed to be for reasons other than 
arthritis, osteoporosis or joint disease.  We also identified an additional 12 DLB cases with no 
reported unexplained falls prior to death (Table 2).  This group with likely no or minimal 
autonomic dysfunction was compared with those DLB subjects, who had clear evidence of 
autonomic dysfunction or repeated unexplained falls.  We could not find any cases diagnosed 
with PDD, AD, VaD or mixed dementia and without evidence of autonomic dysfunction and 
had come to post-mortem.   Furthermore, we identified 17 similar age controls with no 
evidence of reported falls, syncope or autonomic dysfunction (Table 2).  We could not find 
any control subjects, who were clinically assessed in the FASS for autonomic function or had 
falls or syncope and had had a post-mortem.   There were also no dementia cases tested in the 
FASS without autonomic dysfunction and had had an autopsy.  
Patients suspected of autonomic dysfunction with recurrent symptoms of syncope or 
falls had evidence of CSH or OH or both (Table 1).  CSH was diagnosed by an exaggerated 
haemodynamic response to longitudinal carotid sinus massage (CSM).  The exaggerated 
response was defined as >3 seconds of asystole (cardioinhibitory CSH) or a fall in systolic 
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blood pressure in excess of 30 mmHg whilst supine or 50 mmHg whilst in the upright 
position (vasodepressor CSH) during 5 seconds of carotid sinus stimulation by longitudinal 
massage over the carotid sinus (24, 28, 29, 37).  OH was defined as >30 mmHg drop in 
systolic blood pressure after an active stand test (Head-up tilt test) (11, 54).  Patients 
diagnosed with OH had undergone CSM and were confirmed not meet the clinical diagnostic 
criteria for CSH.   The mean interval between the time of autonomic function assessment and 
death was 1.92 years with a range from 0 to 7 years.  Almost 80% of the subjects died 3 years 
after they were assessed in the FASS.  The neuropsychometric assessments included the 
revised Cambridge Cognition Examination (CAMCOG) battery and Mini-Mental State 
Examination (MMSE).   Sub-scores for cognitive domains including memory, orientation and 
other domains of executive function were generated from the total scores (3).   The suspected 
clinical diagnosis of dementia was confirmed at   monthly clinicopathological consensus 
meetings where clinicians met with the pathologists to designate a final diagnosis in 
accordance with current criteria including the diagnostic and statistical manual of mental 
disorders, 4th Edition (DSM-IV).  
Study subjects were participants of the Newcastle longitudinal prospective dementia 
series.  They had a clinical diagnosis of either DLB, PDD, mixed dementia (Mixed), AD or
VaD.  VaD subjects were participants of the Newcastle Cognitive Function After Stroke 
study (3).  Age-matched control subjects aged >70 years were either part of previous 
prospective studies or based on unrelated brain donations to the Newcastle Brain Tissue 
Resource (NBTR).  They were included as controls if they had not been diagnosed with 
autonomic dysfunction, cognitive impairment or any neurological or psychiatric illness.  
Ethics approval was granted by local research ethics committees of the Newcastle upon Tyne 
NHS Foundation Hospitals Trust.  Permission for use of brains for post-mortem research was 
also granted by consent from the participants themselves or next-of-kin or family member.  
Brain tissues were retained in and obtained from the NBTR. 
 
Magnetic Resonance Imaging   
A total of 42 subjects who had post-mortem had undergone brain MRI in life.  T2-weighted 
MRI images (T2WI) were obtained in each case, and WMH volumes (vWMHs) estimated 
using previously validated in house software (12). The mean time from MRI scans to death 
(years + SEM) for all the subjects was 6.4 +0.6 years.  For each group this was as follows:  
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DLB 3.6 +0.7 years; PDD 4.3 +1.0 years; Mixed 4.6 +0.6 years; AD 8.1 +1.1 years and VaD 
6.4 +1.3 years.  For controls, without autonomic dysfunction it was 12.2 +1.4 years (n=5). 
The percentage of WMH volume per total brain volume (%vWMH/vTB) in disease cases was 
calculated.  We then performed correlation analysis between WMH volume and vascular 
pathology scores from all the demented subjects with autonomic dysfunction (Figure 2). 
 
Brain tissues and Neuropathological analysis 
Neuropathological assessment was carried out as described previously (3).  Briefly, 
haematoxylin and eosin (H&E) staining was used for assessment of structural integrity and 
infarcts, Nissl and Luxol Fast blue staining for cellular patterns and myelin loss, 
Bielschowsky’s silver impregnation and amyloid-く for Consortium to Establish a Registry for 
Alzheimer’s Disease (CERAD) rating of neuritic plaques, Gallays stain for neuritic pathology, 
and tau immunohistochemistry for Braak staging of neurofibrillary tangles.  Large sections 
from the frontal, temporal (including hippocampal formation), parietal and occipital lobes, 
caudate-putamen, brain stem including midbrain, pons and medulla oblongata, and 
cerebellum were examined from sampled regional blocks as identified in the Newcastle brain 
map (20, 42).   The clinical diagnosis of DLB and PDD were confirmed according to 
established criteria (30).  The clinical diagnosis of AD was confirmed on evidence of 
significant Alzheimer’s-type pathology incorporating Braak stages V–VI, moderate-severe 
CERAD (26) and high ABC scores per National Institute of Aging-Alzheimer’s Association 
guidelines (36), in the general absence of significant vascular pathology (Table 2).  The 
clinical diagnosis of vascular dementia (VaD) was made when there were multiple or cystic 
infarcts, lacunae, border-zone infarcts, microinfarcts and small vessel disease, and 
pathologically confirmed as Braak stage ≤ IV (20, 21).  Mixed AD and VaD case was 
classified when there was sufficient degree of pathology to reach Braak V–VI and significant 
vascular pathology (6).  We also included cases with Mixed dementia, who met two or more 
neuropathological diagnostic criteria for DLB, PDD and AD.  
Vascular pathology scores were derived from the presence of vascular 
lesions/pathologies in brain areas, including the frontal lobe at the level of the olfactory bulbs, 
temporal lobe at level of the anterior hippocampus, and basal ganglia at level of mamillary 
body. Lesions including arteriolosclerosis, cerebral amyloid angiopathy (CAA), perivascular 
haemosiderin deposition, perivascular space dilatation in the deep and juxtacortical WM, 
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myelin loss, and cortical micro (<0.5 mm), small (<5 mm) and large (>0.5 cm) infarcts were 
recorded with increasing severity resulting in greater scores (10).  These measures were 
compatible with the recently established vascular cognitive impairment neuropathology 
consortium criteria (46).  The vascular pathology scores were determined as detailed 
previously (10) with >95% agreement between scoring performed by VD and RNK.  CAA 
was scored using the system described previously (25).   Tissues from control subjects had 
occasional ageing-related pathology and were classified as ‘no pathological diagnosis’ (Table 
2).  Except for neuropathological examination (TP, RHP, PI and RNK), all subsequent 
morphological analyses were always undertaken under operator blinded conditions.  Samples 
were identified with coded sequential numbers.  In addition, at least two of both positive and 
negative controls were included to monitor the quality of staining. 
 
Assessment of vascular sclerotic index (SI) 
H&E stained coronal frontal lobe (Brodmann area 9) sections were analysed to assess SI in a 
total of ~4,000 brain vessels, essentially as described previously (8, 56).  Twenty images 
from each entire depth of the cerebral cortex and the deep WM were randomly captured using 
a bright field microscope (Leitz DIALUX 20, Leica) with a 10x objective lens coupled to a 
lumenera infinity digital camera (Lumenera Corporation, Canada).  Using VasCalc software 
(56), internal diameter and external diameter of each vessel was measured in three opposing 
axis.  Sclerotic index (SI) was calculated using the following formula: SI = (External 
diameter - Internal diameter) / (External diameter).  Three SI values were calculated from 
three measured axis in each vessel and averaged.   The inter-rater reliability between the 
assessors was 0.9 either DV and RK (SVD pathology scores) or YH and RK (SI scores). 
 
Statistical analysis 
Statistical analysis was carried out using SPSS (IBM, version 23.0, IBM Corporation, 
Armonk, NY, USA) with the level of significance set at P<0.05. First, distribution of values 
was tested using the Shapiro-Wilk test followed by one-way analysis of variance (one-way 
ANOVA) with post-hoc Tukey’s tests for normally distributed values or Kruskall-Wallis H 
tests for non-normally distributed values to compare data amongst autonomic dysfunction 
plus dementia and control group. Student’s t-test or Mann-Whitney U test was used for 
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normally or non-normally distributed data respectively to assess the differences between 
cortex and WM data.  Spearman’s rho correlation was used to assess the relationship between 
WM hyperintensity volumes and vascular pathology.  Pearson’s correlation was used to 
assess the correlation between vascular pathology and microinfarcts/microbleeds. 
Anonymized data will be shared by request from any qualified investigator.  All the data we 
have generated in this study have been included in this paper. 
 
Results 
Clinical features in the autonomic dysfunction plus dementia subjects 
Tables 1 and 2 provide the mean age and gender distributions of all the dementia subjects
with relevant clinical manifestations.  We noted that the mean age of PDD subjects was 
marginally lower compared to controls and other autonomic dysfunction plus dementia 
subjects (†P<0.01) (Table 1 and 2).  Of the 77 dementia subjects tested in the FASS, 29 
(38%) had evidence of both OH and CSH (Table 1).  The total CAMCOG and MMSE scores 
indicated all subjects had evidence of dementia at least 6 months prior to death.  There were 
no differences in CAMCOG memory and executive sub-scores amongst the autonomic 
dysfunction plus dementia groups (Table 1).  We further noted that on average 55% of the 
autonomic dysfunction plus dementia subjects exhibited hypertension and often had more 
than one other vascular disease risk factor including diabetes mellitus (DM), ischaemic heart 
disease (IHD) and smoking (Table 1). The frequency of hypertension in DLB without falls 
subjects was 33%, which was not different compared with that in dementia subjects who had 
autonomic dysfunction (Chi-square test).  
 
Cerebrovascular Pathological changes in Dementia with Autonomic Dysfunction 
Table 2 provides details of clinically tested autonomic dysfunction subjects and ageing 
controls assessed for SVD or microvascular pathology.  None of the control subjects had 
reported unexplained falls in life or had been tested in the FASS.  Subjects with dementia 
exhibited the expected pathology defining each type of disease.  The Mixed and AD subjects 
had the highest amount of neurofibrillary tangle (Braak stage) and neuritic or amyloid く 
plaque burden (Table 2).  The DLB, PDD and VaD groups had relatively lower burdens of 
AD-related hallmark pathologies and there was even less in ageing controls (*P<0.01; 
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**P<0.01) (Table 2).   In addition, nigral Lewy body pathology and neuronal loss were 
characteristically most severe in DLB, PDD and Mixed dementia subjects (Table 2).  Of the 
13 VaD subjects clinically diagnosed with autonomic dysfunction, 3 had some degree of 
Lewy body pathology (Table 2).    
VaD subjects expectedly exhibited the highest vascular and WM pathology scores 
(10).   However, remarkably all neurodegenerative dementia groups including DLB, PDD, 
Mixed and AD had high vascular pathology scores compared to ageing controls (‡P<0.01) 
(Table 2).  AD subjects had the highest ABC scores (36) and the greatest frequency of 
moderate to severe CAA (Table 2).  The types of vascular changes seen in subcortical regions 
in the autonomic dysfunction plus dementia subjects predominantly constituted those akin to 
SVD or microangiopathy, which included arteriolosclerosis, intimal thickening, fibroid 
necrosis, hyalinisation, perivascular spacing,  microinfarcts, WM rarefaction and cerebral 
amyloid angiopathy (10) (Figure 1A, a-f).  WM scores incorporating demyelination (17) were 
also greater in the dementia cases compared to controls.  Variable calcification was present in 
numerous vessels within the extrapyramidal regions particularly in and vicinity of the globus 
pallidus (Figure 1B, a-d) that we also observed, albeit to a lesser degree in normal ageing 
controls.  The diameters of the calcified vessels ranged 40 to 160 たm.  However, distribution 
of the vascular pathology scores in different brain regions indicated that higher scores were 
evident in the frontal lobe and the basal ganglia (Figure 1C).  There was high predilection for 
microinfarcts in the frontal lobe WM as well as the basal ganglia across all the dementias.   
Further verification of our observations on clinically tested subjects was evident from 
retrospective assessment of DLB subjects, who had had no apparent autonomic dysfunction 
(Table 2) and of demented subjects who had had repeated unexplained falls in life (Table 2).  
The vascular pathology features and scores in most of the dementia subjects were similar or 
higher compared to those who were clinically tested in the FASS (Table 2).  We also could 
not find differences in SVD features in demented individuals whether they were clinically 
tested in the FASS or experienced unexplained falls as proxy for autonomic dysfunction.  
However, the key observation was that DLB subjects without reported unexplained falls or
autonomic dysfunction, had lower vascular pathology scores compared to dementia subjects 
who had autonomic dysfunction.  The vascular pathology scores in DLB subjects without 
autonomic dysfunction were also not different from ageing controls (P=0.236) (Figure 1C).   
We also found a positive correlation between severity of CAA and haemosiderin deposition 
(proxy for microbleeds) (r=0.88, P=0.01) but not between CAA and microinfarcts (P>0.05).  
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We further noted that the degree of arteriolosclerosis was strongly correlated with numbers of 
microinfarcts (r=0.87, P=0.012) (Table 2). 
 
Correlation between Vascular pathological changes and WMH volumes upon MRI 
To strengthen the evidence that WMHs associated with the various dementias in life (Figure 
2A) reflected greater SVD or microvascular pathology, we tested the relationship between 
vWMHs determined by T2WI MRI and vascular pathology scores evaluated after post-
mortem in those subjects who exhibited autonomic dysfunction.  We found there was a 
positive correlation (と= 0.40, P=0.016) between vWMH and vascular pathology scores across 
the dementias (Figure 2B).   However, there was no clear relationship between vWMH and 
any of the other neurodegenerative disease markers such as tau or g-synuclein pathology 
(P>0.05).     
 
Sclerotic Index and autonomic dysfunction plus dementia 
We then quantified the degree of arteriolosclerosis using the SI (Figure 3A) in the deep WM 
and entire depth of the cortex of the frontal lobe.  The SI was consistently higher by 40-50% 
in all of the autonomic dysfunction plus dementia subjects compared to controls in both the 
frontal cortex and the WM (**P<0.01 and ††P<0.01 respectively) (Figure 3B).  Dementia 
subjects exhibited higher SI values in the cortex compared to the WM, particularly in AD 
subjects (¶P<0.05), whereas controls showed similar SI values in both the cortex and WM 
(Figure 3B).  However, it was notable that DLB subjects without falls exhibited similar SI 
values as ageing controls and lower SI values, particularly in the WM compared to all 
dementia with evidence of autonomic dysfunction (‡P<0.035) (Figure 3B). 
 
Discussion 
We previously reported that deep WMHs correlated with autonomic dysfunction in DLB 
subjects (24).  In this study, we provide robust evidence for the presence of significantly 
greater degree of SVD pathology including WM changes in dementia subjects with clinical 
evidence of concomitant autonomic dysfunction.  The remarkable finding is that irrespective 
of common dementia type whether DLB, PDD, Mixed dementia, AD or VaD they all 
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exhibited greater SVD type of pathological changes in the presence of autonomic dysfunction.  
This was corroborated by low vascular pathology scores and SI values in DLB subjects 
without evidence of autonomic dysfunction. Whereas the highest burden of SVD pathology 
(51) consisting of microinfarcts, lacunar infarcts, severe arteriolosclerosis, WM rarefaction 
and perivascular spacing was present in VaD, it was rather surprising that subjects diagnosed 
with neurodegenerative dementias including PDD, DLB and AD exhibited these similar 
microvascular changes particularly severe arteriolosclerosis and perivascular spacing.   SI 
values were higher by 45-50% signifying moderate-severe arteriolosclerosis in dementia 
cases with autonomic dysfunction.  Arteriolosclerosis and microinfarcts are strongly 
associated with cognitive impairment (5, 19, 52), and were consistent features across all 
dementias.  Vascular pathology scores, particularly in the WM were also increased and 
correlated with vWMHs in those demented subjects with autonomic dysfunction.   These 
observations collectively suggest arterial wall changes and thickening may impact on blood 
rheology to impair cerebral blood flow and perfusion (20).  
With reference to other features of SVD such as CAA, except in AD, dementia 
subjects with and without autonomic dysfunction exhibited similar CAA pathology to ageing 
controls.  This further suggested that CAA was not necessarily a factor in the observed 
arteriosclerotic differences in demented subjects with and without autonomic dysfunction.  
While, we observed strong correlations between arteriolosclerosis and microinfarcts and 
between CAA and haemosiderin deposition or microbleeds, we did not observe correlations 
between CAA and microinfarcts (40, 47).  The latter is probably because we had low 
numbers of cases in the analysis and had included VaD subjects, who showed relatively low 
CAA but high burden of microinfarction.   The frequency of hypertension in ‘DLB without 
falls’ group was not different from other dementia groups.  Moreover, DLB subjects without 
falls exhibited similar SI values as ageing controls but had lower SI values, particularly in the 
WM, compared to all dementias with concomitant of autonomic dysfunction.  This suggests 
hypertension per se was not necessarily a factor in the observed differences in SVD 
pathology in demented subjects with and without autonomic dysfunction. 
             Large vessel disease may also contribute to SVD type of changes in the WM and to 
microinfarcts (20, 51, 57).  In comparison to the neurodgenerative dementias, VaD subjects 
bear greater degrees of large vessel disease i.e. intracranial and extracranial atherosclerotic 
disease.  In a recent study (14), we noted that regardless of severity of carotid artery stenosis, 
most of the infarcts were small (<5mm in size) and most were located in the cerebral cortex.  
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In a previous it was further noted that cerebral atherosclerosis was not only expectedly 
associated with cystic infarcts but importantly microinfarcts (57).  It would appear 
microinfarcts arise from a combination of mechanisms including artery-to-artery embolism, 
cardiogenic embolism and haemodynamic impairment that likely involve microemboli. 
In comparison to ageing controls with no recorded autonomic dysfunction and DLB 
subjects without reported falls, overall our findings indicate SVD pathological changes are 
common in elderly subjects with autonomic dysfunction irrespective of the type of dementia 
they acquire.  This may compound effects of c -existing pathologies including neurofibrillary 
or g-synuclein pathology or amyloid deposits, which albeit may occur even in cases of pure 
autonomic failure such as idiopathic OH or Bradbury-Eggleston syndrome (pure autonomic 
failure causing idiopathic OH) (ROC and RNK, unpublished observations).  It eems 
reasonable to conclude that cerebral SVD changes contribute to the clinical syndrome in 
elderly subjects who develop dementia and exhibit autonomic dysfunction.  While these 
ageing-related SVD changes may not result in overt neurological signs or cerebrovascular 
events except in VaD, they likely collectively contribute to the declining brain health of the 
elderly with autonomic dysfunction.    
Our findings underscore that vascular protection is important in patients who develop 
any type of dementia and are symptomatic or even asymptomatic for autonomic dysfunction.  
We enrolled symptomatic autonomic dysfunction plus obviously demented subjects.  
However, some patients with neurodegenerative diseases and dementia develop autonomic 
dysfunction prior to motor and cognitive symptoms.  A previous study reported that up to 
40% of PD patients with autonomic dysfunction were ‘asymptomatic’, and even 
‘asymptomatic’ autonomic dysfunction caused higher prevalence of falls, worsened activities 
of daily life (ADL) and affected their quality of life (QOL) (31).  In a follow up study (32), 
the severity of autonomic symptoms progressed by 20% over the course of a year and was 
independently associated with impairment in ADLs and QOL.  Symptomatic and 
asymptomatic OH were both associated with increased falls and health care utilization.  Thus, 
‘asymptomatic’ autonomic dysfunction has almost similar detrimental effects to being 
symptomatic.  Importantly, if ‘asymptomatic’ autonomic dysfunction could be established 
clinically at early stages of cognitive impairment, relevant treatment or intervention(s) has the 
potential to prevent further cognitive decline in patients with neurodegenerative dementias. 
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While our study provides good evidence to support our hypothesis in that autonomic 
dysfunction is linked to alterations in the cerebral vasculature of subjects with 
neurodegenerative diseases, it is unclear whether autonomic dysregulation is a consequence 
or an instigator of dementia.  A recent study (38), provided novel evidence for autonomic 
dysfunction in mild cognitive impairment.  This was associated with orthostatic blood 
pressure dysregulation and suggests that dysautonomia is an early feature in the development 
of cognitive dysfunction.   CSH is an important risk factor for hypertension, IHD and 
systemic atherosclerosis (48).  In our cohort, autonomic dysfunction plus dementia subjects 
displayed frequent vascular risk factors.  These may contribute to atherosclerosis in the 
carotid arteries, affecting the baroreceptors (27) and possibly intracranial cerebral arteries to 
cause deep WM changes (15, 24) and worsen cognitive function.  Alternatively, CSH may 
independently cause chronic or episodic hypotension promoting abnormal perfusion with 
resultant changes in cerebral small vessels and the WM leading to cognitive decline.  While 
previous studies have confirmed the association between features of autonomic dysfunction 
e.g. OH and selective cognitive deficits, albeit in PD, they have rejected the hypothesis that 
this is underlined by the development of cerebrovascular disease (43).  The underlying 
mechanism could be mediated by development of cerebrovascular disease induced by chronic 
or episodic hypoperfusion but until now the extent of brain vascular load in PD or DLB 
patients with OH was not elucidated. 
Another hypothesis is that generalised brain g-synuclein pathology or focal g-
synucleinopathy in the sympathetic ganglia relates to autonomic dysfunction and dementia.   
Clinical and post-mortem neuropathological findings in patients with PD and DLB, both 
clinically diagnosed as pure autonomic failure (PAF) revealed that neurodegeneration in PD 
and DLB may originate from outside the CNS in autonomic postganglionic neurons (22).  
Involvement of postganglionic sympathetic nerves including the cardiac sympathetic nerves 
were predominant in PD and PAF (41), suggesting that the cardiac but not the medullary 
sympathetic neurones are affected in people with PD and PAF.  Cardioinhibitory CSH in 
patients with Lewy body pathology was also related to severity of the cardiac sympathetic 
neurons rather than in CNS (44).  Furthermore, severity of autonomic dysfunction was 
associated with cognitive dysfunction in patients with PD (50).  These reports strongly 
support our findings in that PDD and DLB, which exhibit extensive brain Lewy body 
pathology, showed similar SVD pathologies and cognitive dysfunction as those cases with 
autonomic dysfunction plus dementia without significant Lewy body pathology.  Thus, 
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extensive Lewy body pathologies in the brain may not directly affect SVD pathological 
changes to lead to dementia but autonomic dysfunction related cerebral hypoperfusion likely 
contributes to microvascular pathology, WM changes and cognitive decline in patients with 
Lewy body pathology.  It is plausible, however, that the observed SVD pathological changes 
result from neuronal damage in the brainstem nuclei or disruption of the monoaminergic 
neuronal system (27, 35).  While further investigation is necessary, we observed alpha-
synuclein pathology in sympathetic ganglia of some VaD subjects, suggesting autonomic 
dysfunction in VaD could partly result from alpha-synuclein pathology in the sympathetic 
nervous system. 
We emphasise that one of the main limitations of our study is that we were not able to 
find and compare groups of dementia subjects who were tested in the FASS, did not have 
evidence of autonomic dysfunction and had come to post-mortem.  As suggested by several 
clinical studies (cited above), high numbers of dementia patients may be ‘asymptomatic’ for 
autonomic dysfunction and it is likely that they bear considerable burden of SVD pathology.  
We previously demonstrated the spectrum of vascular pathology in different dementias 
including VaD, AD and DLB (10).   In that previous post-mortem cohort, while we were not 
aware whether any of the patients had autonomic dysfunction or were asymptomatic for it, on 
the whole they tended to exhibit relatively low SVD pathology scores.  Another limitation is 
that we did not quantify microvascular pathology in all the regions of the brain used to score 
vascular pathology.  Such analysis is profoundly cumbersome but in accord with our previous 
hypothesis (13), we concentrated on the deep WM of the frontal lobe and incorporating the 
centrum semiovale.  Finally, in terms of elucidating some mechanistic approaches we did not 
have enough frozen tissues from cases without clear evidence of autonomic dysfunction  to 
substantiate study power and enable biochemical assays of myelin degrading proteins or 
gliovascular unit markers to demonstrate consequences of microvascular damage (13, 17).   
Autonomic functions are regulated in the brainstem, e.g. medulla and its nuclei (34).  
In patients with CSH, tau pathology was evident in the medullary baroreflex nuclei (35) and 
medullary vessels were degenerated in patients with multiple system atrophy (MSA) (33).  
Microvascular changes in the brainstem also relate to or are caused by autonomic dysfunction.  
A future expanded analysis of SVD pathological changes involving other brain regions, 
particularly in the brainstem in this cohort may provide more evidence to elucidate the 
pathophysiological mechanisms and impact of autonomic dysfunction on microvascular 
changes in dementia patients.   
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Conclusions 
In summary, autonomic dysfunction irrespective of final diagnosis of dementia type is 
associated with consistent higher burden of SVD pathological changes, particularly in the 
deep WM.  These SVD changes do not necessarily manifest into overt clinical signs but 
likely add to the dementia syndrome.  Our findings implicate that autonomic dysfunction is 
an important risk factor of chronic cerebral hypoperfusion, which may differentially affect 
neurodegenerative processes to produce the end-stage pathology.  We propose the importance 
of assessing autonomic dysfunction in patients with dementia, particularly at an early stage.  
Treatment for detrimental autonomic dysfunction (even when it is asymptomatic) 
implementing stricter control of vascular risk factors, pacemakers, life-style intervention or 
pharmacological approaches might be effective therapeutic strategies to reduce SVD during 
ageing and prevent or slow down cognitive decline in patients with autonomic dysfunction 
plus dementia, in addition to reducing their immediate risk of falls. 
. 
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Table 1:  Clinical features in the autonomic dysfunction plus dementia subjects assessed in the FASS 
 
  
 
          Variable All 
dementias 
DLB PDD Mixed AD VaD 
Number of subjects 77 16 13 17 18 13 
Age, years, mean (range) 82.3 (64-98) 79.6 (69-96)‡ 72.8 (64-81)† 83.0 (72-93) 87.8 (76-96) 88.1 (75-98) 
OH / CSH / OH and CSH, 
number 
58, 42, 29 12, 10, 7 11, 5, 3 12, 11, 8 14, 11, 9 9, 5, 2 
Total CAMCOG score 
(/100), mean (range) 
54.2 (20-80) 53.8 (24-80) 61.1 (39-74) 51.0 (23-68)* 44.0 (20-73) 61.2 (25-80) 
Memory sub-score (/27), 
mean (range) 
13.7 (4-23) 14.9 (8-21) 16.2 (9-23) 13.5 (4-23) 10.0 (5-14) 14.1 (4-22) 
Executive sub-score (/28),  
mean (range) 
11.2 (2-19) 12.1 (4-23) 9.6 (5-18) 11.2 (7-15) 12.3 (10-17) 10.6 (2-19) 
MMSE score (/30),  
mean (range) 
13.1 (0-24) 13.8 (6-20) 14.2 (3-20) 11.9 (2-19) 8.5 (0-16) 17.2 (8-24)¶ 
Hypertension, number (%) 42 (55%) 11 (69%) 7 (54%) 7 (41%) 9 (50%) 9 (69%) 
Systolic BP, mean (range) 146 (101-200) 149 (122-187) 152 (101-200) 142 (109-186) 141 (110-165) 146 (131-172) 
Diastolic BP, mean (range) 76 (51-120) 74 (60-86) 82 (57-120) 74 (53-98) 72 (51-95) 76 (52-92) 
Other VRF, number 
(smoking / DM / IHD) 
32/5/15 7/0/4 6/1/3 6/1/3 5/3/2 8/0/3 
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All dementia subjects had clinical evidence of autonomic dysfunction.  All dementias group represent all causes of dementia including 
DLB, PDD, Mixed, AD and VaD; Mixed dementia: 7 =AD+DLB, 6 =AD+VaD, 3=AD+DLB+VaD and 1= PD+DLB+VaD. 
Age, †P<0.01 vs Control, DLB, Mixed, AD and VaD; ‡P<0.01 vs AD and VaD; P=0.057, Mixed vs AD; P=0.053, Mixed vs VaD; OH, 
orthostatic hypotension; CSH, carotid sinus hypersensitivity; ‘OH / CSH / OH and CSH, number’ indicates number of cases who had 
OH / CSH / both OH and CSH in each group. For example, in DLB group, OH / CSH / OH and CSH are described as 12, 10, 7. This 
means 12 cases in DLB had OH, 10 subjects confirmed to have CSH and 7 had evidence to have both OH and CSH (OH and CSH 
overlapped in some cases); Total CAMCOG score, *P=0.034 vs PDD, *P=0.028 vs VaD; CAMCOG executive and memory subscore, 
n.s. between groups; MMSE score, ¶P=0.041 vs DLB, ¶P=0.021 vs Mixed, ¶P=0.003 vs AD; Hypertension, number (%),  n.s. between 
groups (Chi-square test);  Systolic and Diastolic BP, n.s. between groups. Clinical features other than age and gender in Controls and 
DLB without falls cases were not completely available as they were not assessed at the falls and syncope clinic (FASS). 
Abbreviations:  AD, Alzheimer’s disease; BP, blood pressure; CAMCOG, revised Cambridge Cognition Examination; DLB, 
Dementia with Lewy Bodies; DM, diabetes mellitus; F, female; IHD, ischaemic heart disease; M, male; Mixed, Mixed dementia; 
MMSE, Mini-Mental State Examination; PDD, Parkinson’s disease with dementia; VaD, Vascular dementia; VRF, vascular risk 
factor; WML, white matter lesion.  
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Table 2 
 
Neuropathological features of all dementia cases and similar age controls in the study 
          Variable Controls 
DLB 
without 
Falls 
All 
dementias DLB PDD Mixed
粁 AD VaD 
Number of subjects 17 12 100 24 18 22 18 18 
Age, years, mean (range) 
86.9  
(72-99) 
80.0  
(74-90)& 
82.0  
(64-98) 
79.6  
(69-96)‡ 
74.6  
(64-89)† 
83.4  
(72-93) 
87.8  
(76-96) 
85.8  
(71-98) 
Gender, number (F/M) 13 / 4 1 / 11 52 / 48 11 / 13 9 / 9 16 / 6 9 / 9 7 / 11 
Autonomic Dysfunction 
(n=)§ 
0 0 100 24 18 22 18 18 
Braak Stage, mean 
(range) 
1.9 (0-4) 3.0 (0-6) 3.3 (0-6) 2.2 (0-4) 2.0 (0-4) 4.8 (2-6)* 5.6 (5-6)** 1.6 (0-4) 
CERAD, mean (range) 0.5 (0-2) 1.2 (0-2) 1.7 (0-3) 1.5 (0-3)思 0.5 (0-2) 2.6 (0-3)* 2.9 (2-3)** 0.8 (0-3) 
Alzheimer’s Disease 
Neuropathologic 
Changes; A, B, C 
(mean)即 
A0.5, 
B1.2, C0.5 
A1.2, 
B1.6, C1.2 
A1.5,  
B1.8, C1.7 
A0.9,  
B1.3, C1.5 
A0.4, 
B1.1, C0.5 
A2.5, 
B2.6, C2.6 
A3,  
B3, C3 
A0.6, 
B1.2, C0.8 
Vascular pathology 
score,  
mean (range)即 
6.7  
(0-10)‡ 
8.1  
(5-10)& 
11.4  
(5-18) 
9.9  
(5-13) 
10.8  
(7-17) 
11.9  
(7-15) 
11.2  
(6-16) 
13.6  
(10-18)¶ 
White matter lesion 
score, 
mean (range) 
0.5 (0-2)§ 1.6 (1-3) 2.2 (0-3) 2.0 (1-3) 2.1 (1-3) 2.1 (0-3) 1.8 (0-3) 2.9 (2-3)ね 
White matter/Vascular 
lesions, moderate - 
severe (%) 
17.6** 41.7* 94 83 94 91 72 100 
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Lewy body pathology,  
number 
(limbic/neocortical) 
0 / 0 2 / 7 16 / 36 3 / 19 5 / 10 5 / 7 0 / 1 3 / 0 
SN neuronal loss (n=), 
(none/mild/moderate/ 
severe) 
N/A 3/1/3/5 19/25/28/24 0/4/11/8 0/1/4/12 3/5/9/4 7/8/2/0 9/7/2/0 
CAA, total (%) 17.6 8.3 18.6 8.3 5.6 18.2 66.7** 27.8 
CAA, moderate-severe 
(%) 
5.8 8.3 10.1 0.0 5.6 9.1 38.9** 16.7 
Arteriolosclerosis, 
moderate-severe (%) 
5.9** 25.0 60.6 45.9 61.1 63.4 61.1 66.7 
Microinfarct, total (%) 35.3** 25.0** 81.1 79.1 88.9 77.3 66.7 100* 
Microinfarct, moderate-
severe (%) 
0.0* 0.0* 30.5 25.0 33.3 27.2 15.6 76.9** 
Haemosiderin deposition 
(microbleeds), total (%) 
0.0 0.0 15.0 8.3 11.1 9.1 33.3** 16.7 
Brain only necropsy (%) 100 25 72.0 70.8 88.9 95.4 66.7 33.3 
Intracranial MCA 
stenosis, moderate-severe 
(%) 
N/A 16.7 14.0 4.2 5.6 0.0 11.1 90.9 
Extracranial ICA 
stenosis, moderate-severe 
(%) 
N/A 0.0 16.8 N/A 0.0 N/A 11.1 100 
g-Synuclein pathology in 
the sympathetic ganglia, 
moderate-severe (n=) 
N/A N/A 5 N/A 1 N/A N/A 4 
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§All dementia subjects had clinical symptoms or evidence of autonomic dysfunction.  粁Mixed dementia group represents: 7=AD+DLB, 
7=AD+VaD, 4=AD+DLB+VaD, 3=DLB+VaD and 1=PD+DLB+VaD.  
Age, †P<0.01 vs Control, DLB, Mixed, AD and VaD;  ‡P<0.01 vs AD and VaD; &P<0.01 vs AD and VaD; Braak Stage, **P<0.01 vs 
Control, DLB without Falls, DLB, PDD and VaD; **P<0.05 vs Mixed; *P<0.01 vs Control, DLB and PDD; *P<0.01 vs DLB without 
Falls and VaD; CERAD, **P<0.01 vs Control, DLB, PDD and VaD; *P<0.01 vs Control, DLB, PDD and VaD; 思P<0.05 vs Control;  
思P<0.01 vs PDD; 即Alzheimer’s Disease Neuropathologic Changes (36); 即Vascular Pathology Score (10), ‡P<0.01 vs DLB, PDD, 
Mixed, AD and VaD; &P<0.01 vs PDD, Mixed, AD and VaD; ¶P<0.05 vs DLB without Falls, DLB and PDD; White matter lesion 
score, §P<0.01 vs DLB without Falls, DLB, PDD, Mixed, AD and VaD; ねP<0.01 vs DLB without Falls, DLB, PDD, Mixed and AD;  
White matter/Vascular lesions, **P<0.01 vs Control, DLB, PDD, Mixed, AD and VaD; *P<0.05 vs Control, DLB, PDD, Mixed, AD 
and VaD (Chi-square test); Lewy body pathology, only the number of limbic/neocortical cases are shown. Fifteen Controls, 7 Mixed, 
15 AD and 14 VaD cases had no Lewy body pathology.  Two controls, 1 DLB, 2 Mixed and 1 AD showed Lewy body pathology in 
brain stem.  Data were not available for 1 case in DLB and PDD groups due to limited autopsy; Neuronal loss in the substantia nigra, 
data was not available for 1 case in each group other than VaD due to limited autopsy. CAA total (%) and CAA moderate-severe (%), 
**P<0.01 (Chi-square test); Arteriolosclerosis moderate-severe (%), **P<0.01 (Chi-square test); Microinfarct total (%) and CAA 
moderate-severe (%), **P<0.01, *P<0.05 (Chi-square test); Microbleeds total (%), **P<0.01 (Chi-square test).   
Abbreviations:  AD, Alzheimer’s disease; CAA, cerebral amyloid angiopathy; CERAD, Consortium to Establish a Registry for 
Alzheimer’s Disease; DLB, Dementia with Lewy Bodies; F, female; ICA, internal carotid artery; M, male; Mixed, MCA, middle 
cerebral artery; Mixed dementia; PDD, Parkinson’s disease with dementia; SN, substantia nigra; VaD, Vascular dementia; WML, 
white matter lesion.  
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Figure Legends 
 
Figure 1: Spectrum of SVD pathology (subcortical cerebrovascular lesions) in 
autonomic dysfunction plus dementia subjects.  A (a-f), Representative images (H&E 
staining) of different vascular pathologies in frontal WM (a-d) and basal ganglia (e and f) 
observed in autonomic dysfunction plus DLB and PDD subjects.  A (a), vascular wall 
thickening with perivascular spacing; A (b), perivascular spacing; A (c), small infarct 
(arrows); A (d), perivascular microinfarct; A (e), microvascular hyalinosis with perivascular 
spacing; A (f), rarefaction (arrows).  B (a-d), Representative images (H&E stain) of 
microvascular changes and variable calcification observed in DLB and PDD subjects.  B (a-
d), microvascular hyalinosis; B (b, c and d), calcification in the vessel wall.  C, Bar chart 
showing the total vascular pathology scores and distribution of individual vascular pathology 
scores in different regions of the brain.  All dementias with autonomic dysfunction groups 
showed consistently higher total (¶P<0.008) and individual vascular pathology scores 
compared to controls, particularly in both the frontal lobe and the basal ganglia (** P<0.016 
and ††P<0.000 respectively).  In the temporal lobe, DLB, Mixed, AD and VaD subjects 
showed higher vascular pathology scores compared to controls (‡P<0.019).  Vascular 
pathology scores in the hippocampus remained same across all dementias and control 
subjects.  High scores were evident in VaD subjects who also exhibited lacunar infarcts.  
Subjects with dementia also exhibited microinfarcts particularly in the frontal WM and basal 
ganglia with scores of 5/6 and 3/4 respectively (10). Total and individual vascular pathology 
scores were not different between controls and DLB without Falls.  Scale bar represents 100 
µm (A, a-f) and 20 µm (B, a-d). 
 
Figure 2: Relationship between WM hyperintensity volumes and vascular pathology in 
autonomic dysfunction.  A (a-f), Axial views of T2-weighted brain MRI images at the level 
of basal ganglia and corona radiata to illustrate degrees of vWMHs in different dementias (b-
f) in comparison to a control subject without autonomic dysfunction (a).  The mean 
percentage of vWMH per total brain volume and vascular pathology scores in the controls 
(n=5) was 10.4% and 8.8 respectively (a).   B, Correlational analysis between percentage of 
vWMH per total brain volume and vascular pathology scores of demented subjects with 
autonomic dysfunction.  Spearman’s rho correlation analysis revealed that vascular pathology 
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score exhibited a positive correlation with % vWMH per total brain volume (と=0.40, 
P=0.016). 
 
Figure 3:  Assessment of vascular sclerotic index in brain vessels.  A, Representative 
profile of a mildly hyalinised microvessel indicating the dimensions used to determine the 
sclerotic index (SI).  The dotted lines mark inner diameters of the vessel.  The normal lines 
indicate external diameters. Scale bar represents 50 µm. B, Histogram showing SI values in 
the WM and the cortex in controls and autonomic dysfunction plus dementia groups.  All 
dementias with autonomic dysfunction groups showed consistently higher mean SI values 
compared to controls in both the WM and the cortex (** P<0.005 and ††P<0.005 respectively).  
SI values were not different between controls and DLB without Falls in both the WM and the 
cortex. In the WM, DLB without Falls showed lower SI values compared with all dementia 
with autonomic dysfunction groups (‡P<0.035). In autonomic dysfunction plus dementia 
subjects, higher SI was evident in the cortex compared with WM, particularly in AD subjects 
(¶P=0.019).   
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